| Workshop patients (n = 20) | |
| Age (years), mean (SD) | 40.8 (10.7) |
| Male gender, n (%) | 8 (40.0) |
| Duration of back pain (years), mean (SD) | 6.9 (6.1) |
| IBP according to Calin et al, n (%) | 15 (75.0) |
| IBP according to Rudwaleit et al, n (%) | 14 (73.7) |
| Enthesitis of the heel, ever, n (%) | 8 (40.0) |
| Peripheral oligoarthritis, ever, n (%) | 6 (30.0) |
| Acute anterior uveitis, ever, n (%) | 0 |
| Dactylitis, ever, n (%) | 2 (10.0) |
| Psoriasis, ever, n (%) | 1 (5.0) |
| Inflammatory bowel disease, ever, n (%) | 1 (5.0) |
| Family history of SpA, n (%) | 6 (30.0) |
| Good response to NSAIDs, n (%) | 16 (80.0) |
| HLA-B27 positive, n (%) | 11 (55.0) |
| Elevated CRP, n (%) | 5 (25.0) |
| Definite radiographic sacroiliitis according to modified New York criteria, n (%) | 3 (15.0) |
| Active inflammatory lesions on MRI of sacroiliac joints, n (%) | 9 (45.0) |
| Amor ⩾6 points, n (%)† | 8 (40.0) |
| Amor ⩾5 points, n (%)‡ | 15 (75.0) |
| ESSG criteria fulfilled, n (%) | 16 (80.0) |
*All clinical parameters including imaging results as assessed by the local organising rheumatologist, before patients were seen by the ASAS experts; †6 or more Amor points defines definite SpA; ‡5 or more Amor points defines probable or definite SpA.
Amor, Amor criteria11 for SpA; CRP, C-reactive protein; ESSG, European Spondyloarthropathy Study Group; HLA, human leukocyte antigen; IBP, inflammatory back pain; NSAID, non-steroidal anti-inflammatory drug; SpA, spondyloarthritis.